GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (LTS:0JXZ) » Definitions » Investments And Advances

Galapagos NV (LTS:0JXZ) Investments And Advances : €50.9 Mil (As of Mar. 2025)


View and export this data going back to . Start your Free Trial

What is Galapagos NV Investments And Advances?

Galapagos NV's Investments And Advances for the quarter that ended in Mar. 2025 was €50.9 Mil.

Galapagos NV's quarterly Investments And Advances increased from Sep. 2024 (€49.1 Mil) to Dec. 2024 (€253.1 Mil) but then declined from Dec. 2024 (€253.1 Mil) to Mar. 2025 (€50.9 Mil).

Galapagos NV's annual Investments And Advances increased from Dec. 2022 (€0.0 Mil) to Dec. 2023 (€13.6 Mil) and increased from Dec. 2023 (€13.6 Mil) to Dec. 2024 (€253.1 Mil).


Galapagos NV Investments And Advances Historical Data

The historical data trend for Galapagos NV's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV Investments And Advances Chart

Galapagos NV Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Investments And Advances
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.95 - - 13.58 253.12

Galapagos NV Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Investments And Advances Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 51.38 49.13 253.12 50.86

Galapagos NV Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.


Galapagos NV Business Description

Address
Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.

Galapagos NV Headlines

No Headlines